migraine treatment

SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...

NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...

London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...

NEW YORK, March 5, 2026 Kallyope announced that it will present Phase 2b clinical trial results for its investigational...